Kang Myung Soo, Hong Su Jin, Kim Dae Yong, Han Jae Pil, Choi Moon Han, Kim Hee Kyung, Ko Bong Min, Lee Moon Sung
Digestive Disease Center and Research Institute, Departments of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Gyeonggi-do, Korea.
J Dig Dis. 2015 Jan;16(1):7-13. doi: 10.1111/1751-2980.12208.
To determine the long-term outcome after endoscopic submucosal dissection (ESD) in patients with early gastric cancer (EGC) according to the pathological extent.
ESD were performed in 280 patients with 309 EGC. The tumors were classified by pathological severity based on absolute indication (AI), expanded indication (EI) or beyond expanded indication (BEI). The therapeutic outcomes among the three groups were analyzed.
The complete resection rates of EGC were 96.4%, 78.7% and 41.2% in the AI-EGC, EI-EGC and BEI-EGC groups, respectively (P = 0.000). En bloc resection rates were 97.6%, 87.4% and 86.3% in the AI-EGC, EI-EGC and BEI-EGC groups, respectively (P = 0.023). The 5-year tumor recurrence rates were 1.8%, 1.5% and 15.4% in the AI-EGC, EI-EGC and BEI-EGC groups, respectively (P = 0.000). The 5-year disease-specific survival rates were 100%, 100% and 97.4% in the AI-EGC, EI-GEC and BEI-EGC groups, respectively (P = 0.088). The 5-year disease-free survival rates were 98.2%, 98.5% and 84.6% in the AI-EGC, EI-EGC and BEI-EGC groups, respectively (P = 0.000).
ESD was effective and safe in treating AI-EGC and EI-EGC, but there was a comparatively high rate of recurrence after ESD in the BEI-EGC group. However, long-term outcomes of patients with BEI-EGC that did not receive additional surgery were better than those with an natural course of EGC. Thus, ESD may be considered for specific BEI-EGC patients at high risk for surgery.
根据病理范围确定早期胃癌(EGC)患者内镜黏膜下剥离术(ESD)后的长期结局。
对280例患者的309处EGC进行ESD。根据绝对适应证(AI)、扩大适应证(EI)或超扩大适应证(BEI),依据病理严重程度对肿瘤进行分类。分析三组的治疗结局。
AI-EGC组、EI-EGC组和BEI-EGC组EGC的完整切除率分别为96.4%、78.7%和41.2%(P = 0.000)。AI-EGC组、EI-EGC组和BEI-EGC组的整块切除率分别为97.6%、87.4%和86.3%(P = 0.023)。AI-EGC组、EI-EGC组和BEI-EGC组的5年肿瘤复发率分别为1.8%、1.5%和15.4%(P = 0.000)。AI-EGC组、EI-GEC组和BEI-EGC组的5年疾病特异性生存率分别为100%、100%和97.4%(P = 0.088)。AI-EGC组、EI-EGC组和BEI-EGC组的5年无病生存率分别为98.2%、98.5%和84.6%(P = 0.000)。
ESD治疗AI-EGC和EI-EGC有效且安全,但BEI-EGC组ESD后的复发率相对较高。然而,未接受额外手术的BEI-EGC患者的长期结局优于EGC自然病程患者。因此,对于手术高风险的特定BEI-EGC患者可考虑行ESD。